

## ENA 2022 Scientific programme

### Wednesday 26 October 2022

#### 10: Clinical Trial Methodology Workshop: The role of ctDNA in clinical trials

10:00 - 12:00

Room 111 + 112

- Chair: Saskia Litière (Belgium)  
Chair: Marie Morfouace (Germany)
- 10:00 **ctDNA in clinical trial practice today**  
Marie Morfouace (Germany)
- 10:20 **ctDNA as a biomarker for patient selection in the neo-adjuvant/adjuvant setting** virtual  
Michail Ignatiadis (Belgium)
- 10:40 **ctDNA as an endpoint in the adjuvant setting**  
Coralie Poncet (Belgium)
- 11:00 **Is there a role for ctDNA in RECIST?**  
Elena Garralda (Spain)
- 11:20 **Panel discussion: ctDNA in clinical trial practice tomorrow**  
Panel: Saskia Litière (Belgium)  
Panel: Marie Morfouace (Germany)  
Panel: Michail Ignatiadis (Belgium)  
Panel: Coralie Poncet (Belgium)  
Panel: Elena Garralda (Spain)  
Panel: Concepcion Biurrun (Spain)

#### 15: Opening Ceremony: Welcome and opening of the ENA 2022 conference

13:00 - 13:05

Room 111 + 112

Chair: Ruth Plummer (United Kingdom)

#### 20: Michel Clavel Lecture: Michel Clavel Lecture

13:05 - 13:50

Room 111 + 112

Chair: Ruth Plummer (United Kingdom)  
**Cancer initiation, immune evasion and metastases: insights from TRACERx**  
Keynote Speaker: Charles Swanton (United Kingdom)

#### 30: Keynote Lecture: Keynote Lecture

13:50 - 14:35

Room 111 + 112

Chair: Lillian L. Siu (Canada)  
**Clinical and translational advances in cancer immunotherapeutics**  
Keynote Speaker: Lisa Butterfield (USA)

#### 40: Plenary Session 1: STING Agonists

14:45 - 16:15

Room 111 + 112

- Chair: Samuel Bakhoun (USA)  
Chair: Ignacio Melero (Spain)
- 14:45 **Local immunotherapy: translation of the dsRNA analog BO112**  
Ignacio Melero (Spain)
- 15:05 **An orally available non-nucleotide STING agonist with antitumor activity: A mechanistic study**  
Gottfried Schroeder (USA)
- 15:25 **E7766**  
Kim Dae-Shik (USA)
- 15:45 **Sting agonists early phase study**  
Funda Meric-Bernstam (USA)
- 16:05 **Q&A**

#### 50: Mini Symposium: ADC variety

16:15 - 17:45

Room 111 + 112

- Chair: Anthony W. Tolcher (USA)  
Chair: Valentina Boni (Spain)
- 16:15 **Antibody drug conjugates - beyond cytotoxic payloads**  
Martha Neagu Aristide (USA)
- 16:35 **Antibody-drug conjugates and ISACs**  
Anthony W. Tolcher (USA)
- 16:55 **Novel ADCs**  
Shyra Gardai (USA)
- 17:15 **ADC prodrugs**  
Valentina Boni (Spain)
- 17:35 **Q&A**

#### 60: Mini Symposium: Drug Development of Mutant Specific versus Target Selective Inhibitors

16:15 - 17:45

Room 212

- Chair: Elena Garralda (Spain)  
Chair: Udai Banerji (United Kingdom)
- 16:15 **KRAS**  
Pasi A. Jänne (USA)
- 16:35 **PIK03CA**  
Lillian Smyth (USA)
- 16:55 **FGFR**  
Ben Wolf (USA)
- 17:15 **RET**  
Vivek Subbiah (USA)
- 17:35 **Q&A**

## Thursday 27 October 2022

### 80: Plenary Session 2: Allogeneic Genetically Engineered Cells for ACT

08:00 - 09:30

Room 111 + 112

- Chair: David Quach (USA)  
Chair: Denis Migliorini (Switzerland)
- 08:00 **'off-the-shelf' Allogeneic car t cells: development and challenges**  
Stéphane Depil (France)
- 08:20 **Allogeneic CAR T cells: An alternative to overcome challenges of CAR T cell therapy in glioblastoma**  
Denis Migliorini (Switzerland)
- 08:40 **Expansion and persistence of allogeneic therapeutic T-cells via expression of a CD30.CAR**  
David Quach (USA)
- 09:00 **Genetically engineered NK therapy for immunotherapy-resistant cancers** virtual  
Rafet Basar (USA)
- 09:20 **Q&A**

### 90: Plenary Session 3: Proffered Papers

10:00 - 11:30

Room 111 + 112

- Chair: Elizabeth Budde (USA)  
Chair: Ivan Diaz Padilla (Switzerland)
- 10:00 **A radiohapten capture system for CAR T cells that tracks them in vivo and improves efficacy**  
K. Kurtz, L. Eibler, M. Dacek, L. Carter, S. Cheal, D. Veach, S. Qureshy, J. Han, E. Reynaud, S. Verma, M. McDevitt, B. Punzalan, D.B. Vargas, B.H. Santich, S. Monette, A. Kesner, N.K. Cheung, S. Larson, D. Scheinberg, S. Krebs (USA)
- 10:10 **Q&A**
- 10:15 **ROS induction as a strategy to target persister cancer cell metabolism**  
O. Eichhoff, C. Stoffel, L. Briker, P. Turko, G. Karsai, V. Paulitschke, N. Zamboni, Z. Balazs, A. Tastanova, R. Wegmann, J. Mena, V. Viswanathan, C. TuPro, M. Krauthammer, S. Schreiber, T. Hornemann, M. Distel, B. Snijder, R. Dummer, M. Levesque (Switzerland)
- 10:25 **Q&A**
- 10:30 **Integrated molecular and clinical analysis of BRAF-mutant glioma in adults**  
K. Schreck, P. Langat, T. Li, V. Bhave, C. Pratilas, C. Eberhart, W.L. Bi (USA)
- 10:40 **Q&A**
- 10:45 **Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.**  
L. Pala, T. De Pas, E. Pagan, C. Catania, V. Bagnardi, F. Conforti (Italy)
- 10:55 **Q&A**
- 11:00 **Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling**  
J. Chan, S. Zaidi, J. Love, J. Zhao, M. Setty, K. Wadosky, A. Gopalan, Z.N. Choo, S. Persad, O. Chaudhary, T. Xu, I. Masilionis, M. Morris, L. Mazutis, R. Chaligne, Y. Chen, D. Goodrich, W. Karthaus, D. Pe'er, C. Sawyers (USA)
- 11:10 **Q&A**
- 11:15 Discussant: Josep Maria Piulats Rodriguez (Spain)

## 100: Plenary Session 4: Emerging New Targets

11:30 - 13:00

Room 111 + 112

- Chair: James L. Gulley (USA)  
Chair: Christophe Le Tourneau (France)
- 11:30 **Mannose receptor and innate antitumor immunity**  
Udo Rudloff (USA)
- 11:45 **CBLB inhibitors**  
Adam Sharp (United Kingdom)
- 12:00 **AsiDNA**  
Christophe Le Tourneau (France)
- 12:15 **NEdd8 inhibitors**  
Alexey Danilov (USA)
- 12:30 **YAP TAZ pathway**  
Christophe Massard (France)
- 12:45 **Q&A**

## 103: Posters in the Spotlight session: Poster in the Spotlight 1

13:30 - 14:00

- Moderator: Elena Garralda (Spain)
- 13:30 **Impact of orthotopic versus subcutaneous implantation on patient-derived xenograft transcriptomic profile** PB001  
Y. Sheng, W. Qian, S. Guo (China)
- 13:35 **Q&A**
- 13:40 **Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in Diffuse Large B Cell Lymphoma (DLBCL), by analyzing the spatial arrangement of CD37 and CD20 positive cells using deep learning** PB002  
A. Pokorska-Bocci, S. Micallef, M. Dymkowska, Y. Gabay, R. Gluskin, Y. Blum, A. Laniado, E. Dicker Sagy, A. Bart, T. Dicker, I. Rotbein, A. Achtenberg, O. Zelichov (Switzerland)
- 13:45 **Q&A**
- 13:50 **BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC** PB003  
F. Siegel, S. Siegel, K. Graham, G. Karsli-Uzunbas, D. Korr, J. Schroeder, U. Boemer, R.C. Hillig, J. Mortier, M. Niehues, S. Golfier, V. Schulze, S. Menz, A. Kamburov, M. Hermsen, A. Cherniak, K. Eis, A. Eheim, M. Meyerson, H. Greulich (USA)
- 13:55 **Q&A**

## 105: AACR-Chemistry in Cancer Research Working Group (CICR) Town Hall Meeting and Net: Inhibiting KRAS: Past, Present and Future Opportunities

13:00 - 14:30

Room 212

- 13:00 **Networking Reception**

- 13:20 **Welcoming remarks, overview of 2022-2023 CICR working group programs and activities**  
Adrian Gill (USA)
- 13:30 **Targeting RAS proteins: Biology breakthroughs and drug discovery innovations**  
Saskia Brachmann (Switzerland)
- 13:40 **Targeted Protein Degradation as an Approach to KRAS Modulation**  
Katrina L. Jackson (USA)
- 13:50 **Therapeutic opportunities targeting oncogenic KRAS beyond KRASG12C**  
Norbert Kraut (Austria)
- 14:10 **Panel discussion**

**110: Workshop 1: Drug development in low-middle income countries - challenges and opportunities**

15:00 - 16:30 Room 111 + 112

---

- Chair: Daniel Araujo (Brazil)  
Chair: Bishal Gyawali (Canada)
- 15:00 **Clinical research environment in Latin-America and opportunities for drug development**  
Daniel Araujo (Brazil)
- 15:15 **The national cancer grid of India - impact in oncology research**  
C.S. Pramesh (India)
- 15:30 **Challenges and opportunities for drug development in Asia**  
Herbert Loong (Hong Kong)
- 15:45 **Advantages and pitfalls of drug development in LMIC**  
Bishal Gyawali (Canada)
- 16:00 **Reducing disparities in eligibility for cancer immunotherapy clinical trials for people living with HIV**  
Thomas Odeny (USA)
- 16:15 **Discussion**

**120: Workshop 2: Using ctDNA in directing therapy of advanced cancer**

15:00 - 16:30 Room 212

---

- Chair: Lillian L. Siu (Canada)  
Chair: Alberto Bardelli (Italy)
- 15:00 **Circulating tumor ctDNA analysis to direct therapy for breast cancer (plasmaMATCH)**  
Nick Turner (United Kingdom)
- 15:15 **ctDNA in metastatic MSI-H cancers**  
Francois-Clement Bidard (France)
- 15:30 **Circulating tumor DNA analysis in the development of new drugs for advanced GI cancer** virtual  
Takayuki Yoshino (Japan)
- 15:45 **ctDNA guiding immunotherapy in urothelial carcinoma**  
Bernadett Szabados (United Kingdom)
- 16:00 **Discussion**

**130: Workshop 3: AI and Computational Analysis**

17:00 - 18:30 Room 111 + 112

---

- Chair: Pedro Cutillas (United Kingdom)  
 Chair: Eric Stahlberg (USA)
- 17:00 **ATOM**  
 Eric Stahlberg (USA)
- 17:15 **Computational genomics**  
 Eytan Ruppin (USA)
- 17:30 **Computational biology**  
 Nuria Lopes-Bigas (Spain)
- 17:45 **Academic perspective clinical trials**  
 Emiliano Calvo (Spain)
- 18:00 **Discussion**

**140: Workshop 4: Liquid biomarker and Single-Cell Analysis in cancer research**

17:00 - 18:30

Room 212

- Chair: Minetta Liu (USA)  
 Chair: Marc Oliva (Spain)
- 17:00 **Liquid biomarker for early detection**  
 Minetta Liu (USA)
- 17:15 **Liquid biomarker for stratification in clinical trials** virtual  
 Takayuki Yoshino (Japan)
- 17:30 **Liquid biomarkers for cancer characterization and monitoring**  
 Maximilian Diehn (USA)
- 17:45 **MRD and different ctDNA technologies**  
 Marc Oliva (Spain)
- 18:00 **Discussion**

**Friday 28 October 2022**

**170: Plenary Session 5: Project Optimus from the FDA: how will this affect clinical trials and drug development?**

08:00 - 09:30

Room 111 + 112

- Chair: Lesley Seymour (Canada)  
 Chair: Josep Tabernero (Spain)
- 08:00 **Project Optimus guidance from FDA** virtual  
 Mirat Shah (USA)
- 08:15 **Clinical pharmacology perspective**  
 Mark J. Ratain (USA)
- 08:30 **Clinical trialists' perspective**  
 Josep Tabernero (Spain)

08:45 **Dose selection for oncology drugs- a critical choice**  
Matthew Ellis (USA)

09:00 **Panel Discussion**  
Panel: Lesley Seymour (Canada)  
Panel: Josep Taberero (Spain)  
Panel: Mirat Shah (USA)  
Panel: Mark J. Ratain (USA)  
Panel: Matthew Ellis (USA)  
Panel: Inez Font Rodriguez (Spain)

### **180: Workshop 5: Modernising eligibility criteria for early phase oncology clinical trials**

10:00 - 11:30

Room 111 + 112

Chair: S. Percy Ivy (USA)  
Chair: Emiliano Calvo (Spain)

10:00 **Why should eligibility criteria for early phase trials be broadened?**  
Emiliano Calvo (Spain)

10:10 **Overview of the ASCO/friends of cancer research process for modernizing eligibility criteria and how their findings devolved to clinical practice**  
S. Percy Ivy (USA)

10:20 **Performance status vs. fitness tools, is one better than the other?**  
Heidi Klepin (USA)

10:30 **How changes in evaluation of renal function affect early phase trial eligibility**  
Jan Beumer (USA)

10:40 **Trial pathfinder, data-driven approach to broaden restrictive eligibility criteria using artificial intelligence** virtual  
Ruishan Liu (Canada)

10:50 **Generalizability of modernized eligibility criteria to achieve inclusiveness in clinical trials**  
Olga Kholmanskikh (Belgium)

11:00 **Panel discussion**  
Moderator: Jaap Verweij (Belgium)

### **190: Workshop 6: How to optimize the use of preclinical models for drug development**

10:00 - 11:30

Room 212

Chair: Chris Lord (United Kingdom)  
Chair: Emile Voest (Netherlands)

10:00 **Ex-vivo avatars to understand immune checkpoint blockade mechanism of action**  
Daniela Thommen (Netherlands)

10:15 **High-throughput drug sensitivity and CRISPR screens**  
Chris Lord (United Kingdom)

10:30 **Organoids as preclinical model for drug discovery**  
Emile Voest (Netherlands)

10:45 **Deciphering the spatiotemporal control of tumor immune phenotype by live imaging**  
Christine Moussion (USA)

11:00 **Discussion**

## 200: Plenary Session 6: New Drugs on the Horizon

11:30 - 13:30

Room 111 + 112

- Chair: Ruth Plummer (United Kingdom)  
Chair: Elena Garralda (Spain)
- 11:30 **T cell engager and NK cell engager**  
Elizabeth Budde (USA)
- 11:45 **Personalized cancer vaccines**  
Patrick Ott (USA)
- 12:00 **New DNA damage response targets**  
Thomas Helleday (Sweden)
- 12:15 **Development of MRT-2359, a gspt1 molecular glue degrader, to target myc-driven malignancies**  
Filip Janku (USA)
- 12:30 **STAR0602, a novel TCR agonist antibody, demonstrates potent anti-tumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset**  
J.L. Gulley, A. Bayliffe, R. Donahue, Y.T. Tsai, K. Liu, M. Katraggada, J. Hsu, L.L. Siu, E.J. Wherry, R. Chopra, J. Schlom, Z. Su (USA)
- 12:40 **Q&A**
- 12:45 **Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors**  
E. Garralda, V. Moreno, G. Alonso, E. Corral, T. Hernandez-Guerrero, J. Ramon, B. Doger de Spéville, E. Martinez, L. Soucek, M. Niewel, E. Calvo (Spain)
- 12:55 **Q&A**
- 13:00 **Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors**  
A. Drilon, B. Besse, D.R. Camidge, S.H.I. Ou, S.M. Gadgeel, M.L. Johnson, A. Calles, M.J. De Miguel, A.I. Spira, E. Felip, G. Lopes, A.J. Van der Wekken, Y.Y. Elamin, J. Green, Y. Sun, J. Soglia, V.W. Zhu, J.J. Lin (USA)
- 13:10 **Q&A**
- 13:15 Discussant: Udai Banerji (United Kingdom)

## 205: Posters in the Spotlight session: Poster in the Spotlight 2

14:00 - 14:30

- Moderator: Minetta Liu (USA)
- 14:00 **HER2 as a therapeutic target in bladder cancer** PB007  
Z. Chen, X. Tang, J.R. Christin, S.P. Gao, C.E. Chu, M.F. Berger, N.D. Schultz, M.M. Shen, H.A. Al-Ahmadie, G. Iyer, K. Kim, D.B. Solit (USA)
- 14:05 **Q&A**
- 14:10 **Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer** PB008  
M. Tagliamento, M. Aldea, V. Verge, A. Bayle, F. Blanc-Durand, A. Marinello, J. Hadoux, Y. Loriot, D. Vasseur, C. Nicotra, C. Smolenschi, P. Martin-Romano, A. Hollebecque, S. Ponce, L. Lacroix, E. Rouleau, C. Marzac, A. Italiano, B. Besse, J.B. Micol (France)
- 14:15 **Q&A**
- 14:20 **DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations** PB005  
N. Ngoi, P.G. Pilie, S.A. Piha-Paul, E.E. Dumbrava, S. Fu, D.S. Hong, D.D. Karp, A. Naing, S. Pant, J. Rodon Ahnert, V. Subbiah, A.M. Tsimberidou, C. Salguero, C.V. Brown, W.E. Hoadley, A. Johnson, Y. Yuan, S.N. Westin, F. Meric-Bernstam, T.A. Yap (USA)



14:25 Q&A

**210: Plenary Session 7: Late Breaking and Proffered Papers**

15:00 - 16:30

Room 111 + 112

Chair: Lillian L. Siu (Canada)

Chair: Ruth Plummer (United Kingdom)

- 15:00 **NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers** virtual  
T.A. Yap, N. Ngoi, E.E. Dumbrava, D.D. Karp, J. Rodon Ahnert, S. Fu, D.S. Hong, A. Naing, S. Pant, S.A. Piha-Paul, V. Subbiah, A.M. Tsimberidou, D. Dufner, J. Rhudy, S. Gore, S.P. Ivy, Y. Yuan, S.N. Westin, G.B. Mills, F. Meric-Bernstam (USA)
- 15:10 **Q&A**
- 15:15 **CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors**  
F. Meric-Bernstam, J.P. Eder, A. Vandross, M. Gara, S. Gayle, P. Pearson, A. DeCillis, A. Tolcher (USA)
- 15:25 **Q&A**
- 15:30 **Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K**  
K. Kalinsky, W. Zihan, C. McCourt, E.P. Mitchell, J.J. Wright, L.A. Doyle, R.J. Gray, V. Wang, L.M. McShane, L.V. Rubinstein, D. Patton, P.M. Williams, S.R. Hamilton, B.A. Conley, C.A. Arteaga, L.N. Harris, P.J. O'Dwyer, A.P. Chen, K.T. Flaherty (USA)
- 15:40 **Q&A**
- 15:45 **A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations**  
F. Opdam, J. Heymach, M. Barve, Y.L. Wu, N. Gibson, B. Sadrolhefazi, J. Serra, K. Yoh, N. Yamamoto (Germany)
- 15:55 **Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)**  
B.C. Cho, J. Lin, D.R. Camidge, V. Velcheti, B. Solomon, S. Lu, K.H. Lee, S.W. Kim, S. Kao, R. Dziadziuszkzo, M. Beg, M. Nagasaka, E. Filip, B. Besse, C. Springfield, S. Popat, J. Wolf, D. Trone, S. Stopatschinskaja, A. Drilon (South Korea)
- 16:05 **NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma**  
M. Reig, S. Damian, D. Roberti, S. Maruzzelli, P. Crivori, L. Gianellini, M.T. De Pietro, N. Personeni, M. Sanduzzi-Zamparelli, M. Duca, L. Disconzi, A. Montagnoli, A. Galvani, E. Ardini, A. Isacchi, E. Colajori, C. Davite, L. Mahnke, L. Rimassa (Spain)
- 16:15 Discussant: Irene Braña Garcia (Spain)